<DOC>
	<DOCNO>NCT00003005</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy consist cordycepin plus pentostatin treating patient refractory acute lymphocytic chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy With Cordycepin Plus Pentostatin Treating Patients With Refractory Acute Lymphocytic Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety , maximum tolerate dose , adverse effect , toxicity cordycepin , give 1 hour follow fix dose adenosine deaminase inhibitor pentostatin , patient refractory TdT positive leukemia . II . Determine single multiple dose pharmacokinetics cordycepin give 1 hour follow fix dose pentostatin . III . Characterize select whole blood blast cell metabolic parameter serially relation cordycepin/pentostatin administration . IV . Measure quantify clinical response refractory TdT positive leukemia patient follow cordycepin/pentostatin administration . OUTLINE : This dose escalation study . Each treatment course 28 day length . On day 1-3 pentostatin administer 5 minute IV bolus follow 1 hour later 1 hour infusion cordycepin IV . An escalate dose pentostatin give fix dose cordycepin desire level adenosine deaminase inhibition observe . After determine , dose escalation schedule cordycepin initiate determine maximum tolerate dose ( MTD ) give combination pentostatin . The MTD determine number patient exhibit dose limit toxicity severity toxicity . PROJECTED ACCRUAL : Approximately 30 patient accrue .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cordycepin</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : TdT positive acute lymphocytic leukemia blastic chronic myelogenous leukemia Failed least one standard treatment PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky great 70 % Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Transaminases great 2.5 time normal Renal : Creatinine great 1.5 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : Ejection fraction great 40 % Other : Not pregnant nursing No serious concurrent illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since radiation therapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>TdT positive adult acute lymphoblastic leukemia</keyword>
</DOC>